-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nutriband (NASDAQ:NTRB) Vs. Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Contrast
Nutriband (NASDAQ:NTRB) Vs. Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Contrast
Nutriband (NASDAQ:NTRB) and Advanced Biomedical Technologies (OTCMKTS:ABMT ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Profitability
This table compares Nutriband and Advanced Biomedical Technologies' net margins, return on equity and return on assets.
Get Nutriband alerts:
Net Margins | Return on Equity | Return on Assets | |
Nutriband | -321.58% | -40.78% | -37.55% |
Advanced Biomedical Technologies | N/A | N/A | N/A |
Earnings and Valuation
This table compares Nutriband and Advanced Biomedical Technologies' gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Nutriband | $1.42 million | 19.42 | -$6.18 million | ($0.80) | -4.38 |
Advanced Biomedical Technologies | $120,000.00 | 20.68 | -$670,000.00 | N/A | N/A |
Advanced Biomedical Technologies has lower revenue, but higher earnings than Nutriband.
Volatility & Risk
Nutriband has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Nutriband and Advanced Biomedical Technologies, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Nutriband | 0 | 0 | 0 | 0 | N/A |
Advanced Biomedical Technologies | 0 | 0 | 0 | 0 | N/A |
Institutional & Insider Ownership
2.1% of Nutriband shares are held by institutional investors. 40.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Advanced Biomedical Technologies beats Nutriband on 6 of the 9 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About Advanced Biomedical Technologies
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.
Nutriband(纳斯达克股票代码:NTRB)和Advanced Biomedical Technologies(OTCMKTS: ABMT) 都是小型医疗公司,但哪只股票更好?我们将根据两家公司的估值、收益、股息、风险、盈利能力、分析师建议和机构所有权来比较这两家公司。
盈利能力
此表比较了Nutriband和Advanced Biomedical Technologies的净利润率、股本回报率和资产回报率。
获取Nutriband警报:
净利润率 | 股本回报率 | 资产回报率 | |
Nutriband | -321.58% | -40.78% | -37.55% |
Advanced Biomedical Technologies | 不适用 | 不适用 | 不适用 |
收益和估值
下表比较了Nutriband和Advanced Biomedical Technologies的毛收入、每股收益和估值。
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Nutriband | 142万美元 | 19.42 | -618万元 | ($0.80) | -4.38 |
Advanced Biomedical Technologies | $120,000.00 | 20.68 | -$670,000.00 | 不适用 | 不适用 |
Advanced Biomedical Technologies的收入低于Nutriband,但收益高于Nutriband。
波动性与风险
Nutriband的贝塔系数为0.61,表明其股价的波动性比标准普尔500指数低39%。相比之下,Advanced Biomedical Technologies的贝塔系数为0.77,表明其股价的波动性比标准普尔500指数低23%。
分析师建议
这是MarketBeat.com报道的营养带和先进生物医学技术最近建议的细目。
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Nutriband | 0 | 0 | 0 | 0 | 不适用 |
Advanced Biomedical Technologies | 0 | 0 | 0 | 0 | 不适用 |
机构与内部人持股
2.1%的Nutriband股份由机构投资者持有。Nutriband 40.2%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票的长期表现将好于大盘。
摘要
Advanced Biomedical Technologies在两只股票比较的9个因素中有6个击败了Nutriband。
关于Nutriband
Nutriband Inc.开发一系列透皮药物产品。该公司正在开发的主导产品是Aversa芬太尼,这是一种滥用威慑芬太尼透皮系统,为临床医生和患者提供缓释芬太尼透皮产品,用于治疗需要全天候阿片类药物治疗的慢性疼痛。它还开发其他产品,包括阿维沙丁丙诺啡和阿维沙甲酯;治疗2型糖尿病的埃塞那肽;以及治疗不孕症的卵泡刺激素。Nutriband Inc.与Rambam Med-Tech Ltd.签署了一项开发Rambam封闭式系统传输设备的许可协议。该公司成立于2016年,总部位于佛罗里达州奥兰多。
关于Advanced Biomedical Technologies
高级生物医学技术公司是一家处于发展阶段的公司,设计、开发、制造和销售生物材料内固定设备。它提供聚合物骨接合设备,如外科螺丝、捆绑钢丝、棒和相关医疗设备,用于治疗骨科创伤、与运动相关的医疗、软骨修复和相关治疗,以及重建牙科程序。该公司前身为Geostar矿业公司,并于2009年3月更名为Advanced Biomedical Technologies,Inc.。先进生物医学技术公司成立于2002年,总部设在纽约。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧